Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 109Leukemia 21Recurrence 12Myelodysplastic Syndromes 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neoplasms 5Leukemia, Myeloid 5Hematologic Neoplasms 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Lymphoma 3Leukemia, Biphenotypic, Acute 3Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Hematologic Diseases 2Congenital Abnormalities 2Thrombocytopenia 1Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Pathologic Complete Response 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloid Malignancies 1Meningitis 1Meningeal Neoplasms 1Lymphoma, Mantle-Cell 1

Interventions

Pemetrexed 5ponatinib 4pembrolizumab 4Carboplatin 4Cisplatin 3130-nm albumin-bound paclitaxel 3tetulomab tetraxetan lu-177 2pralsetinib 2osimertinib 2napabucasin 2fludarabine 2ficlatuzumab 2entinostat 2durvalumab 2atezolizumab 2Rituximab 2Paclitaxel 2Lutetium 2Irinotecan 2Immunotherapy 2Imatinib Mesylate 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cyclophosphamide 2Bortezomib 2Bevacizumab 2vorasidenib 1siltuximab 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms by Histologic Type × Cytarabine × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡